Samsung Biologics says its product carbon footprint (PCF) system received validation from Det Norske Veritas (DNV). DNV is an independent, third-party assurance provider that confirmed the PCF system aligns with globally recognized standards.

How Carbon Footprint Was Measured

Among these standards with which Samsung Biologics’ PCF calculation methodology complies are ISO 14067 and PAS 2050. To assess the system’s validity, DNV measured data input, conversion, and output, receiving confirmation of assumptions, methods, and overall approach.

As a CDMO, Samsung Biologics takes an “advanced and systematically developed” approach to carbon accounting. In terms of its impact on biopharmaceutical manufacturing processes, the approach encourages transparent and consistent sustainability reporting.

Samsung Biologics President and CEO John Rim said the goal is greater communication and comparability of product-level carbon footprint data. This, he said, benefits the evolving expectations of clients across the biopharmaceutical value chain.

“Independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide,” Rim said. “This represents the company’s continued focus on building sustainable operations based on established standards, while maintaining reliable and consistent manufacturing. As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration.”

Other Samsung Biologics News

In addition to achieving this validation, Samsung Biologics confirmed in December 2025 that its business is expanding. Namely, the company acquired its first U.S. manufacturing site in a $280 million purchase of Human Genome Sciences from GSK. That transaction, concerning a facility in Rockville, Md., is closing late in the first quarter of 2026.

As for Samsung Biologics’ sustainability efforts, those also recently got recognition outside of the DNV verification. The company received a Platinum rating in an EcoVadis assessment. This places Samsung Biologics in the top 1% of global companies evaluated for sustainability management.